BIOCON vs ORCHPHARMA: Stock Comparison

Biocon Limited vs Orchid Pharma Limited

Live data: 22 July 2026, 3:00 PM IST • Source: NSE and company filings

Biocon Limited is the larger company by market capitalisation. Biocon Limited shows a lower P/E, a higher dividend yield and faster revenue growth, while Orchid Pharma Limited shows a higher ROE, lower leverage and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Biocon Limited and Orchid Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BIOCON is more favourable on 7 of 13 scored metrics and ORCHPHARMA on 6These counts are context-free and are not an overall rating.

Key Differences

Market Cap
BIOCON is the larger company
₹70,989 Cr vs ₹5,072 Cr
P/E Ratio
BIOCON has a lower P/E
185.25x vs 253.09x
P/B Ratio
BIOCON has a lower P/B
2.1x vs 4.04x
EPS
ORCHPHARMA has higher earnings per share
₹4.01 vs ₹2.86
Dividend Yield
BIOCON has a higher dividend yield
0.11% vs 0%
Revenue Growth (TTM YoY)
BIOCON has faster revenue growth
2.3% vs -1.5%
EPS Growth (TTM YoY)
ORCHPHARMA has faster EPS growth
0% vs -72.5%
Qtr Sales Growth
BIOCON has stronger quarterly sales growth
2.25% vs 0.05%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBIOCONORCHPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBIOCONORCHPHARMA
Live Price₹437.25₹1,000.1
Day Change-0.69%-2.24%
Volume51.42 L81,675
52-Week High₹447.15₹1,119.8
52-Week Low₹331₹480
Distance from 52W High-2.21%-10.69%

Valuation

MetricBIOCONORCHPHARMA
Market Cap₹70,989 Cr₹5,072 Cr
P/E Ratio185.25x253.09x
P/B Ratio2.1x4.04x
EPS₹2.86₹4.01
Book Value₹210.14₹253.98
Dividend Yield0.11%0%

Growth

MetricBIOCONORCHPHARMA
Revenue Growth (TTM YoY)2.3%-1.5%
EPS Growth (TTM YoY)-72.5%0%
Qtr Sales Growth2.25%0.05%
Qtr Profit Growth-62%4.26%

Profitability & Leverage

MetricBIOCONORCHPHARMA
ROE1.4%2.12%
ROCE3.75%2.64%
Net Margin2.29%2.51%
Operating Margin20.4%5.07%
Debt to Equity0.45x0.28x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBIOCONORCHPHARMA
Promoter Holding29.73% 0.17 pp69.84%
FII Holding8.16% 0.64 pp0.87% 0.3 pp
DII Holding23.37% 0.7 pp20.25% 0.86 pp
Public Holding23.74% 0.33 pp9.05% 0.55 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Biocon Limited and Orchid Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.